Версия сайта для людей с нарушением зрения
    шрифт
только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Обычная версия
Раздел 17 / 17
Страница 1 / 1

Список литературы

  1. Стойко Ю.М., Кириенко А.И., Илюхин Е.А. и др. Диагностика и лечение тромбофлебита поверхностных вен конечностей // Рекомендации Ассоциации флебологов России. Флебология. 2019. Т. 13, № 2. С. 78–97. DOI: https://doi.org/10.17116/flebo20191302178
  2. Decousus H., Prandoni P., Mismetti P. et al. CALISTO Study Group // Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010, Sep 23. Vol. 363, N 13. P. 1222–1232. DOI: https://doi.org/10.1056/NEJMoa0912072.PMID:20860504
  3. Beyer-Westendorf J., Schellong S.M., Gerlach H. et al. SURPRISE investigators // Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017, Mar. Vol. 4, N 3. P. e105-e113. DOI: https://doi.org/10.1016/S2352–3026(17)30014–5. Epub 2017 Feb 16. PMID: 28219692
  4. Raskob G.E. Angchaisuksiri P., Buller H. et al. ISTH Steering Committee for World Thrombosis Day // Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014, Nov. Vol. 34, N 11. P. 2363–2371. DOI: https://doi.org/10.1161/ATVBAHA.114.304488. PMID: 25304324
  5. Wendelboe A.M., Raskob G.E. Global Burden of Thrombosis: Epidemiologic Aspects // Circ Res. 2016, Apr 29. Vol. 118, N 9. P. 1340–7. DOI: https://doi.org/10.1161/CIRCRESAHA.115.306841. PMID: 27126645
  6. Keller K., Hobohm L., Ebner M. et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany // Eur Heart J. 2020, Jan 21. Vol. 41, N 4. P. 522–529. DOI: https://doi.org/10.1093/eurheartj/ehz236. PMID: 31102407
  7. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО) / Л.А. Бокерия, И.И. Затевахин, А.И. Кириенко [и др.] // Флебология. 2015. Т. 9, № 4–2. С. 1–52. EDN XIOPYZ.
  8. Лебедев А.К., Кузнецова О.Ю. Тромбоз глубоких вен нижних конечностей // Российский семейный врач. 2015. Т. 19, № 3. С. 4–16. EDN VPMKFL.
  9. Delluc A., Ianotto J.-Ch., Tromeur C. et al. Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study // Res. 2018, Apr. Vol. 164. P. 79–84. DOI: https://doi.org/10.1016/j.thromres.2018.02.151. Epub 2018, Mar 2. PMID: 29522910.
  10. Klein A., Shepshelovich D., Spectre G. et al. Screening for occult cancer in idiopathic venous thromboembolism — Systemic review and meta-analysis // Eur J Intern Med. 2017, Jul. Vol. 42. P. 74–80. DOI: https://doi.org/10.1016/j.ejim.2017.05.007. Epub 2017 May 12. PMID: 28502867.
  11. Bozkurt A.K., Hakki T.A., Ismet T.C. et al. National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society // Turk Gogus Kalp Damar Cerrahisi Derg. 2021, Oct 20. Vol. 29, N 4. P. 562–576. DOI: https://doi.org/10.5606/tgkdc.dergisi.2021.22121. PMID: 35096459; PMCID: PMC8762899.
  12. Mosarla R.C., Vaduganathan M., Qamar A. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week // J Am Coll Cardiol. 2019, Mar. 26, Vol. 73, N 11. P. 1336–1349. DOI: https://doi.org/10.1016/j.jacc.2019.01.017. PMID: 30898209; PMCID: PMC7957366.
  13. Kakkos S.K., Gohel M., Baekgaard N. et al. Editor’s Choice — European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis // Eur J Vasc Endovasc Surg. 2021, Jan. Vol. 61, N 1. P. 9–82. DOI: https://doi.org/10.1016/j.ejvs.2020.09.023. Epub 2020 Dec 15. PMID: 33334670.
  14. Lyman G.H. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer // Blood Adv. 2021, Feb 23. Vol. 5, N 4. P. 927–974. DOI: https://doi.org/10.1182/bloodadvances.2020003442. Erratum in: Blood Adv. 2021, Apr 13. Vol. 5, N 7. P. 1953. PMID: 33570602; PMCID: PMC7903232.
  15. Решетняк Т.М. Федеральные клинические рекомендации по лечению антифосфолипидного синдрома. М., 2013.
  16. Tektonidou M.G., Andreoli L., Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults // Annals of the Rheumatic Diseases. 2019. Vol. 7. P. 1296–1304.
  17. Konstantinides S.V., Meyer G., Becattini C. et al. ESC Scientific Document Group 2019 // ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020, Jan 21. Vol. 41, N 4. P. 543–603. DOI: https://doi.org/10.1093/eurheartj/ehz405. PMID: 31504429.
  18. NIH COVID-19 Treatment Guidelines. COVID-19 Treatment Guidelines (nih.gov)
  19. Han H., Yang L., Wu K. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection // Clin Chem Lab Med. 2020, Jun 25. Vol. 58, N 7. P. 1116–1120. DOI: https://doi.org/10.1515/cclm-2020-0188
  20. Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic // J Am Coll Cardiol. 2020, May 12. Vol. 75, N 18. P. 2352–2371. DOI: https://doi.org/10.1016/j.jacc.2020.03.031
  21. Guan W.J., Ni Z.Y., Hu Y. et al. China Medical Treatment Expert Group for Covid-19 // Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020, Apr 30. Vol. 382, N 18. P. 1708–1720. DOI: https://doi.org/10.1056/NEJMoa2002032
  22. Tang N. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy // J Thromb Haemost. 2020, May. Vol. 18, N 5. P. 1094–1099. DOI: https://doi.org/10.1111/jth.14817
  23. Nopp S., Moik F., Jilma B. et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis // Res Pract Thromb Haemost. 2020, Sep 25. Vol. 4, N 7. P. 1178–1191. DOI: https://doi.org/10.1002/rth2.12439
  24. Spyropoulos A.C., Anderson F.A., FitzGerald G. et al. IMPROVE Investigators // Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011, Sep. Vol. 140, N 3. P. 706–714. DOI: https://doi.org/10.1378/chest.10–1944
  25. Gibson C.M., Spyropoulos A.C., Cohen A.T. et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification// TH Open. 2017, Jun 28. Vol. 1, N 1. P. e56–e65. DOI: https://doi.org/10.1055/s-0037–1603929
  26. Raskob G.E., Spyropoulos A.C., Zrubek J. et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE // Design, rationale, and clinical implications. Thromb Haemost. 2016, Jun 2. Vol. 115, N 6. P. 1240–1248. DOI: https://doi.org/10.1160/TH15–09–0756

Для продолжения работы требуется вход / регистрация